When a Drug Shows Promise: What Happens Next in Clinical Trials?Associate Professor Nicholas Wilcken was the Study Chair of the HERA clinical trial, which tested the drug Herceptin and delivered a major breakthrough for women with HER2-positive breast cancer.In this podcast, Associate Professor Wilcken discusses what happens when a drug is proven effective in a clinical trial. Tune in for a deep dive into this important topic.Like this episode? ⁠⁠Follow Breast Cancer Trials on Social Media: Instagram:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@breastcancertrials⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Breast Cancer Trials⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Breast Cancer Trials⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@BCTrialsANZ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Guest: Associate Professor Nicholas WilckenThank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about clinical trials research.Find out more: www.breastcancertrials.org.au

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related